First-line TAGRISSO: Watch expert discussions and informational videos
FLAURA Efficacy and Safety Edward Kim, MD, and Kathryn Mileham, MD, of the Levine Cancer Institute in Charlotte, North Carolina, review the compelling data from the FLAURA study. 10 min.
Unmet Need Edward Kim, MD, and Jenna Kramer, RN, of the Levine Cancer Institute in Charlotte, North Carolina, discuss patient impact and the opportunity of the approval of first-line TAGRISSO to help these patients. 10 min.
Subgroup Analysis Edward Kim, MD, and Kathryn Mileham, MD, of the Levine Cancer Institute in Charlotte, North Carolina, present data analyzing first-line TAGRISSO in various patient subgroups from the FLAURA study. 10 min.
The Roles of IO Therapy and EGFR-TKI Discussion Jack West, MD, of the Swedish Cancer Institute, Rachel Sanborn, MD, of the Earle Chiles Cancer Institute, and Hatim Husain, MD, of the University of California, San Diego, discuss the role EGFR TKIs, such as TAGRISSO, may play in patients with metastatic EGFRm NSCLC. 9 min.
Sequencing Panel Discussion Jack West, MD, of the Swedish Cancer Institute, Rachel Sanborn, MD, of the Earle Chiles Cancer Institute, and Hatim Husain, MD, of the University of California, San Diego, explore using TAGRISSO in the first-line setting. 11 min.
CNS Panel Discussion Jack West, MD, of the Swedish Cancer Institute in Seattle, Washington, and colleagues review the CNS response to first-line TAGRISSO in a subset of patients in the FLAURA study. 9 min.
FLAURA Overview In this video, Jack West, MD, of the Swedish Cancer Institute, Rachel Sanborn, MD, of the Earle Chiles Cancer Institute, and Hatim Husain, MD, of the University of California, San Diego, discuss the first-line TAGRISSO efficacy results from the FLAURA study, and its implications for the current treatment landscape. 9 min.
Mechanism of Action See how first-line TAGRISSO works in the body. 7 min.
There are no contraindications for TAGRISSO
Interstitial lung disease (ILD)/pneumonitis occurred in 3.9% of the 1142 TAGRISSO-treated patients; 0.4% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed
Heart rate-corrected QT (QTc) interval prolongation occurred in TAGRISSO-treated patients. Of the 1142 TAGRISSO-treated patients in clinical trials, 0.9% were found to have a QTc >500 msec, and 3.6% of patients had an increase from baseline QTc >60 msec. No QTc-related arrhythmias were reported. Conduct periodic monitoring with ECGs and electrolytes in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval. Permanently discontinue TAGRISSO in patients who develop QTc interval prolongation with signs/symptoms of life-threatening arrhythmia
Cardiomyopathy occurred in 2.6% of the 1142 TAGRISSO-treated patients; 0.1% of cardiomyopathy cases were fatal. A decline in left ventricular ejection fraction (LVEF) ≥10% from baseline and to <50% LVEF occurred in 3.9% of 908 patients who had baseline and at least one follow-up LVEF assessment. Conduct cardiac monitoring, including assessment of LVEF at baseline and during treatment, in patients with cardiac risk factors. Assess LVEF in patients who develop relevant cardiac signs or symptoms during treatment. For symptomatic congestive heart failure, permanently discontinue TAGRISSO
Keratitis was reported in 0.7% of 1142 patients treated with TAGRISSO in clinical trials. Promptly refer patients with signs and symptoms suggestive of keratitis (such as eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye) to an ophthalmologist
Postmarketing cases consistent with Stevens-Johnson syndrome (SJS) and erythema multiforme major (EMM) have been reported in patients receiving TAGRISSO. Withhold TAGRISSO if SJS or EMM is suspected and permanently discontinue if confirmed
Verify pregnancy status of females of reproductive potential prior to initiating TAGRISSO. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TAGRISSO and for 6 weeks after the final dose. Advise males with female partners of reproductive potential to use effective contraception for 4 months after the final dose
Most common adverse reactions (≥20%) were diarrhea, rash, dry skin, nail toxicity, stomatitis, fatigue and decreased appetite
TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test
TAGRISSO is indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy
Please see complete Prescribing Information including Patient Information.
You may report side effects related to AstraZeneca products by clicking here.